Bulgarian cystic fibrosis Pseudomonas aeruginosa isolates: antimicrobial susceptibility and neuraminidase-encoding gene distribution

References

1. Burns J. L., Saiman L., Whittier S., Larone D., Krzewinski J., Liu Z., Marshall S. A., Jones R. N. 2000; Comparison of agar diffusion methodologies for antimicrobial susceptibility testing of Pseudomonas aeruginosa isolates from cystic fibrosis patients. J Clin Microbiol 38:1818–1822
   [Google Scholar]
2. Ciofu O., Fussing V., Bagge N., Koch C., Høiby N. 2001; Characterization of pared mucoid/non-mucoid Pseudomonas aeruginosa isolates from Danish cystic fibrosis patients: antibiotic resistance, β -lactamase activity and ribotyping. J Antimicrob Chemother 48:391–396 [CrossRef]
   [Google Scholar]
3. CLSI 2005 Performance Standards for Antimicrobial Susceptibility Testing , 15th informational supplement, M100–S15 Wayne, PA: Clinical and Laboratory Standards Institute;
   [Google Scholar]
4. CFF 2002 Patient Registry 2001 Annual Data Report Bethesda, MD: Cystic Fibrosis Foundation;
   [Google Scholar]
5. Davies J., Dewar A., Bush A., Pitt T., Gruenert D., Geddes D. M., Alton E. W. 1999; Reduction in the adherence of Pseudomonas aeruginosa to native cystic fibrosis epithelium with anti-asialoGM1 antibody and neuraminidase inhibition. Eur Respir J 13:565–570 [CrossRef]
   [Google Scholar]
6. Govan J. R., Deretic V. 1996; Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia . Microbiol Rev 60:539–574
   [Google Scholar]
7. Johansen H. K., Moskowitz S. M., Ciofu O., Pressler T., Høiby N. 2008; Spread of colistin resistant non-mucoid Pseudomonas aeruginosa among chronically infected Danish cystic fibrosis patients. J Cyst Fibros 7:391–397 [CrossRef]
   [Google Scholar]
8. Lanotte P., Watt S., Mereghetti L., Dartiguelongue N., Rastegar-Lari A., Goudeau A., Quentin R. 2004; Genetic features of Pseudomonas aeruginosa isolates from cystic fibrosis patients compared with those of isolates from other origins. J Med Microbiol 53:73–81 [CrossRef]
   [Google Scholar]
9. Morosini M. I., Garcia-Castillo M., Loza E., Perez-Vazquez M., Baquero F., Canton R. 2005; Breakpoints for predicting Pseudomonas aeruginosa susceptibility to inhaled tobramycin in cystic fibrosis patients: use of high-range E-test strips. J Clin Microbiol 43:4480–4485 [CrossRef]
   [Google Scholar]
10. Pitt T. L., Sparrow M., Stefanidou M. 2003; Survey of resistance of Pseudomonas aeruginosa from UK patients with cystic fibrosis to six commonly prescribed antimicrobial agents. Thorax 58:794–796 [CrossRef]
    [Google Scholar]
11. Ramsey B. W. 1996; Management of pulmonary disease in patients with cystic fibrosis. N Engl J Med 335:179–188 [CrossRef]
    [Google Scholar]
12. Srifuengfung S., Tiensasitorn C., Yungyuen T., Dhirapurta C. 2004; Prevalence and antimicrobial susceptibility of Pseudomonas aeruginosa mucoid and non-mucoid type. Southeast Asian J Trop Med Public Health 35:893–896
    [Google Scholar]
13. Strateva T. 2008; Microbiological and molecular-genetic investigations on the resistance mechanisms and virulence factors in clinical strains of Pseudomonas aeruginosa . PhD thesis Medical University of Sofia;